An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
Status:
Terminated
Trial end date:
2018-02-09
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label extension study of safety and tolerability of lampalizumab
administered by intravitreal (ITV) injection to participants with geographic atrophy (GA) who
have completed the 18-month treatment in Study CFD4870g (GX01456) (NCT01229215) or 24-week
treatment in Study GX29455 (NCT02288559).